NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
NeurAxis (NYSE American: NRXS), a medical technology company specializing in neuromodulation therapies for chronic and debilitating conditions, will be participating in the Lytham Partners Spring 2024 Investor Conference.
The virtual event will take place on May 30, 2024. The company will present a webcast at 9:30 a.m. ET, which can be accessed via the conference's homepage or directly on the webcast platform. The presentation will be available for replay after the event.
Additionally, NeurAxis's management will engage in virtual one-on-one meetings with investors throughout the conference. Interested parties can arrange these meetings through Lytham Partners by contacting them or registering on the conference website.
- NeurAxis's participation in the Lytham Partners Spring 2024 Investor Conference could increase investor visibility and interest in NRXS.
- The webcast presentation and one-on-one meetings provide an opportunity to showcase NeurAxis's neuromodulation therapies.
- The virtual format allows for broader access and convenience for investors globally.
- The impact of virtual conferences might be less significant compared to in-person events, potentially limiting networking opportunities.
- The press release does not mention any new product developments or financial achievements, which might be a concern for investors looking for concrete progress.
CARMEL, Ind., May 21, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.
Company Webcast
The webcasted presentation will take place at 9:30 a.m. ET on Thursday, May 30, 2024. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2024/ or directly at https://wsw.com/webcast/lytham11/nrxs/2139291. The webcast will also be available for replay following the event.
1×1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/spring2024invreg/.
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.
Contacts
Company
NeurAxis, Inc.
info@neuraxis.com
Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com
FAQ
When will NeurAxis participate in the Lytham Partners Spring 2024 Investor Conference?
How can I access NeurAxis's webcast presentation at the Lytham Partners Spring 2024 Investor Conference?
What is the stock symbol for NeurAxis?
Will NeurAxis's webcast presentation be available for replay?
How can I arrange a one-on-one meeting with NeurAxis's management during the Lytham Partners Spring 2024 Investor Conference?
